PE-22-28 10mg

Quickstart Highlights

Reference-linked protocol details for PE-22-28 10mg.

Reference title: PE-22-28 Dosage Chart – 10 mg Vial Protocol | PeptideDosages.com
Product: PE-22-28 10mg vial
A research-use neuropeptide entry for TREK-1/spadin literature and safety review.
Source page: Open source

Recommended Source

This protocol is linked to the workbook reference source below.

PE-22-28 Dosage Chart – 10 mg Vial Protocol | PeptideDosages.com Open source

Dosing & Reconstitution Guide

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read PE-22-28 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week	Daily Dose (µg)	Units (per injection) (mL)
Weeks 1–2	50 µg	1.5 units (0.015 mL)
Weeks 3–4	100 µg	3 units (0.03 mL)
Weeks 5–8	100 µg	3 units (0.03 mL)
Weeks 9–12 (Optional)	150 µg	4.5 units (0.045 mL)
Weeks 13–16 (Optional)	200 µg	6 units (0.06 mL)

Open this dosage and reconstitution chart directly from your account.
Educational guide for reconstitution and daily dosing
Frequency: Inject once daily subcutaneously. This schedule uses a practical 3.0 mL dilution for accurate measurement. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability. Many researchers find 100–150 µg sufficient given PE-22-28’s high potency[4].

Reconstitution Steps

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration. Plan vial quantities from the dosing chart; follow product-specific use-by and sterile-handling instructions.

Peptide Vials (PE-22-28, 10 mg each):
Peptide Vials (PE-22-28, 10 mg each):: 8 weeks ≈ 2 vials
Peptide Vials (PE-22-28, 10 mg each):: 12 weeks ≈ 3 vials
Peptide Vials (PE-22-28, 10 mg each):: 16 weeks ≈ 4 vials
Insulin Syringes (U-100):
Insulin Syringes (U-100):: Per week: 7 syringes (1/day)
Insulin Syringes (U-100):: 8 weeks: 56 syringes
Insulin Syringes (U-100):: 12 weeks: 84 syringes
Insulin Syringes (U-100):: 16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.: 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.: 12 weeks (3 vials): 9 mL → 1 × 10 mL bottle
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.: 16 weeks (4 vials): 12 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
Alcohol Swabs: One for the vial stopper + one for the injection site each day.: Per week: 14 swabs (2/day)
Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 8 weeks: 112 swabs → recommend 2 × 100-count boxes
Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 12 weeks: 168 swabs → recommend 2 × 100-count boxes
Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 16 weeks: 224 swabs → recommend 3 × 100-count boxes
PE-22-28 10 mg
U-100 syringes
Bacteriostatic water
Alcohol swabs
Practice preparing this vial with the verified strength and final volume from this protocol.
Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
Typical daily range: 50–200 µg once daily (gradual titration over 8–16 weeks).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 µg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); protect from light.
PE-22-28 is a synthetic heptapeptide (sequence: GVSWGLR) derived from the sortilin propeptide, engineered as a potent and selective antagonist of TREK-1 potassium channels[4]. Preclinical studies demonstrate rapid antidepressant-like effects, enhanced neurogenesis, and neuroprotection with a favorable safety profile showing no cardiac or metabolic side effects[2][3]. This educational protocol presents a once-daily subcutaneous approach with gradual titration.

Protocol Overview

Concise summary of the once-daily regimen.

Goal: Support rapid neuroplasticity, mood regulation, and neuroprotection through selective TREK-1 inhibition[2][4].
Schedule: Daily subcutaneous injections for 12–16 weeks (8 weeks minimum).
Dose Range: 50–200 µg daily with conservative titration; many find 100–150 µg adequate.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for precise low-volume measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; follow product-specific use-by instructions.

Dosing Protocol

Suggested conservative daily titration approach.

Start: 50 µg daily for Weeks 1–2 to assess tolerance.
Increase: 100 µg daily for Weeks 3–8 (standard maintenance dose).
Optional Titration: 150 µg (Weeks 9–12) or 200 µg (Weeks 13–16) only if well-tolerated and additional effect desired.
Frequency: Once per day (subcutaneous).
Cycle Length: 12–16 weeks; 8 weeks minimum.
Timing: Consistent daily time; rotate injection sites systematically.

Storage Instructions

Proper storage preserves peptide quality and potency.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); follow product-specific use-by and sterile-handling instructions.
Allow vials to reach room temperature before opening to reduce condensation; protect from light.
Bacteriostatic water does not guarantee that a prepared peptide vial remains sterile for a set period. Follow applicable multi-dose vial handling rules; they do not establish this peptide’s chemical shelf life[10].

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each injection; dispose in a sharps container immediately.
Rotate injection sites (abdomen, thighs, upper arms) systematically to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle to prevent leakage.
Document daily dose, site rotation, and any observations to maintain protocol consistency.
Given PE-22-28’s high potency (IC50 ~0.12 nM), conservative dosing is recommended; most preclinical effects occurred at low microgram ranges[4].

How This Works

PE-22-28 functions as a potent and selective antagonist of TREK-1 (KCNK2) two-pore domain potassium channels[2]. By blocking TREK-1, it depolarizes neurons and enhances excitability, leading to increased firing of serotonergic neurons and elevated monoamine neurotransmission[2]. This mechanism produces rapid antidepressant-like effects in preclinical models - within 4 days, PE-22-28 significantly increases hippocampal neurogenesis and synaptogenesis markers, changes typically requiring weeks with conventional antidepressants[4]. The peptide also activates CaMKII/CREB pathways that promote neuronal survival and plasticity[6]. PE-22-28 represents a shortened, optimized analog of spadin with superior potency (IC50 ~0.12 nM versus 40–60 nM for spadin) and longer duration of action (~23 hours versus ~7 hours)[4]. Notably, research also demonstrates neuroprotective effects in stroke models through biphasic dosing that leverages both TREK-1 activation at ultra-low doses and inhibition at standard doses[5].

Observations from preclinical literature and mechanistic studies.
Rapid Antidepressant Effects: Produces behavioral improvements within 4 days in rodent models; reduces immobility in forced swim tests and decreases latency to feed in novel environments[4].
Enhanced Neuroplasticity: Increases hippocampal neurogenesis, synaptogenesis markers (PSD-95), dendritic spine density, and BDNF expression within days[4].
Neuroprotection: In stroke models, preserves dopaminergic neurons, reduces motor deficits, and prevents post-stroke depressive behavior[5].
Favorable Safety Profile: Shows high selectivity with no effects on hERG channels (cardiac safety), no impact on heart rate, blood pressure, glucose regulation, or pain perception in preclinical studies[3]. No TREK-1-related side effects or withdrawal observed[3].
No Human Data: All evidence is from cell culture and animal studies; human safety and pharmacokinetics remain unestablished[1].
Potential Mild Reactions: Subcutaneous administration may occasionally cause minor injection-site reactions (slight redness or tenderness).

Lifestyle Factors

Complementary strategies to support neuroplasticity and mood optimization.

Maintain consistent sleep schedule and prioritize 7–9 hours of quality sleep to support neurogenesis.
Engage in regular physical activity; both aerobic exercise and resistance training enhance BDNF and mood-regulating pathways.
Follow a nutrient-dense diet rich in omega-3 fatty acids, antioxidants, and B-vitamins to support brain health.
Practice stress-management techniques (meditation, mindfulness, therapy) to complement neuroplastic adaptations.
Consider cognitive training or novel learning activities to synergize with enhanced synaptic plasticity.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and injection site with alcohol; allow both to air-dry completely[8][9].
Pinch a skinfold of subcutaneous tissue; insert the needle at 45° (or 90° if using very short needles with ample subcutaneous fat)[8].
Do not aspirate for subcutaneous injections; inject solution slowly and steadily[8].
Rotate sites systematically (abdomen at least 2 inches from navel, front/outer thighs, outer upper arms) to prevent lipohypertrophy and maintain absorption consistency[9].
Given the very small injection volumes (often ≤0.10 mL), technique precision is critical. Consider using 30- or 50-unit insulin syringes for doses under 10 units to improve measurement accuracy.
Withdraw needle at the same angle inserted; apply gentle pressure if needed; dispose of syringe immediately in sharps container.

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

References

These sources provide related context and are not presented as support for a specific statement above.

PE-22-28 Dosage Chart – 10 mg Vial Protocol | PeptideDosages.com Open source
1 Pure Lab Peptides - PE-22-28 (10 mg) product page (research-grade peptide, quality documentation) View Source Open source
2 PLoS Biology (2010) - Mazella et al.: Spadin, a sortilin-derived peptide targeting TREK-1 channels; novel antidepressant mechanism View Source Open source
3 Neuropharmacology (2012) - Moha Ou Maati et al.: Spadin as antidepressant; absence of TREK-1-related side effects View Source Open source
4 Frontiers in Pharmacology (2017) - Djillani et al.: Shortened spadin analogs (PE-22-28); superior TREK-1 inhibition, in vivo stability, antidepressant activity View Source Open source
5 Neuropharmacology (2019) - Pietri et al.: Protective effects on stroke recovery and post-stroke depression induced by sortilin-derived peptides View Source Open source
6 Pharmacological Research (2021) - Daziano et al.: Sortilin-derived peptides promote pancreatic beta-cell survival through CREB signaling pathway View Source Open source
8 CDC - Vaccine administration: subcutaneous injection instruction guide (technique, angle, no aspiration) View Source Open source
9 CDC - 4 Ways to Take Insulin; section on injection site rotation and subcutaneous technique View Source Open source
10 Centers for Disease Control and Prevention - Injection Safety: Clinical Safety and multi-dose vial handling View Source Open source
1 International Journal of Molecular Sciences (2022) - Chang et al.: Potential of heterogeneous compounds as antidepressants; narrative review including TREK-1 modulators View Source Open source
Explore the available research context, protocol variants or comparisons, and practical guides. When vial-size variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.
Research overview
PE-22-28 Peptide: Benefits, Uses, Side Effects, Dosage, and Research Open source
What Is Neuroxelin? An Evidence-Based Guide to the Peptide Blend Open source
Related protocols and comparisons
Neuroxelin (48 mg Vial) Dosage Protocol Open source
Pinealon (20 mg Vial) Dosage Protocol Open source
Semax (5 mg Vial) Dosage Protocol Open source
Semax (10 mg Vial) Dosage Protocol Open source
Selank (5 mg Vial) Dosage Protocol Open source
Selank (10 mg Vial) Dosage Protocol Open source
Practical guides
Single Peptide Dosages Open source
Peptide Dosage & Reconstitution Calculator Open source
How to Reconstitute Peptides Open source
Syringe & Measurement Guide Open source
Peptide Storage Guide Open source
Peptide Dosage Chart Open source
Our research summaries and tools are free. Add Peptide Dosages as a preferred source on Google to keep us close when you need us.
Your trusted source for comprehensive peptide dosage protocols and research information. Empowering researchers with accurate, science-based guidance.
Single Peptides Open source
Peptide Blends Open source
Peptide Stacks Open source
Dosage Calculator Open source
Blog Open source
Beginner's Guide Open source
Reconstitution Guide Open source
Storage Guide Open source
Glossary Open source
FAQ Open source
About Us Open source
Editorial Policy Open source
Contact Us Open source
Get the latest peptide research and protocols delivered to your inbox.
Important Disclaimer: All information provided on PeptideDosages.com is for research and educational purposes only. Not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any new research protocol.
Privacy Policy Open source
Terms & Conditions Open source
Cookie Policy Open source
Disclaimer Open source
PE-22-28 (10 mg Vial) Dosage Protocol
On a phone, your share menu can also include Messages and other installed apps.
Select and copy this public page link.

Contents